List of Fensolvi Kit drug patents

Fensolvi Kit is owned by Tolmar.

Fensolvi Kit contains Leuprolide Acetate.

Fensolvi Kit has a total of 1 drug patent out of which 0 drug patents have expired.

Fensolvi Kit was authorised for market use on 01 May, 2020.

Fensolvi Kit is available in powder;subcutaneous dosage forms.

Fensolvi Kit can be used as method of treating pediatric patients 2 years of age and older with central precocious puberty.

The generics of Fensolvi Kit are possible to be released after 15 October, 2023.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8470359 TOLMAR Sustained release polymer
Oct, 2023

(8 months from now)

Exclusivity Exclusivity Expiration
New Indication (I) May 1, 2023

Drugs and Companies using LEUPROLIDE ACETATE ingredient

Market Authorisation Date: 01 May, 2020

Treatment: Method of treating pediatric patients 2 years of age and older with central precocious puberty

Dosage: POWDER;SUBCUTANEOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic